Open Neurol
A boxed warning is the most serious warning from the Food and Drug Administration
Insurance pathways: If insurance-covered GLP-1 medications are an option for you, does the platform also facilitate access to FDA-approved versions, or only compounded formulations
Plus, despite Lemon Bottle claiming to have excellent safety and efficacy data we could not find any high-quality clinical studies performed on humans that prove this products safety efficacy claims therefore we dont know the potential risks both short-term and long-term with this product
And in studies conducted on another popular weight loss drug called terzepatide (aka, Mounjaro), 5.7 percent of patients reported experiencing hair loss versus less than 1 percent on a placebo
Eligibility for weight loss treatment typically requires a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, or obstructive sleep apnea